We found that mTOR inhibition increased the CD133+ subpopulation in liver tumor cells and potentiated the continuous growth of tumor cells in vivo via preventing differentiation, biased insensitivity of CD133+ subpopulation to rapamycin-induced apoptosis, and increasing the retrodifferentiation of CD133- to CD133+ cells. The gene discussed is PROM1; the disease is neoplasm.